Innovations in Aesthetics

Take a look at some of this year’s innovative products showcased at CCR 2022

In an evolving specialty like aesthetics, practitioners are constantly searching for the latest innovations and products to add to their clinic offerings to improve results and patient wellbeing. A new addition to CCR this October was the Innovation Trail, which showcased 10 new and exciting products, companies and brands that launched innovations this year! We’re casting a spotlight on these new innovations and finding out the science behind them.

ASCEplus SRLV and HRLV by EvoCyte

About ASCEplus SRLV is a skin rejuvenating product containing five billion exosomes in combination with high viscosity hyaluronic acid, 10 types of growth factors, six types of peptides, NAD+, DMAE and glutathione. The company claims it helps improve rosacea, melasma and eczema. ASCEplus HRLV is a scalp care treatment containing 10 billion exosomes with 10 growth factors, 30 types of nutrients, biotin and copper tripeptide. The company explains that the product helps with male and female pattern hair loss.

The science Studies conducted by the company highlight that ASCEplus SRLV exosomes increased the production of collagen by 600% and elastin by 300%. Meanwhile, ASCEplus HRLV exosomes increase dermal papilla hair cell proliferation by 30%, reduce inflammatory cytokines by 55% and normalise the hair cycle.1

What practitioners say Dr Irfan Mian, medical director at Chinbrook Medical Cosmetic Centre, said, “I have been using ASCEplus SRLV exosomes in my clinic for the last five months. The results have been impressive, with patients reporting significantly improved skin quality and looking more youthful.”

AviClear by Cutera

About AviClear is the first US Food and Drug Administration (FDA)-cleared energy device for the treatment of mild, moderate and severe acne. It’s a laser that uses a 1726 nm wavelength to resolve acne at the source by selectively targeting the sebocytes and suppressing sebum production. The device will be launching in 2023.

The science In a clinical study of 104 patients enrolled to undergo three treatments, one, three, six and 12 months apart, 80% of patients had more than 50% reduction in inflammatory lesions with 91% responding after three months.2

What practitioners say Board-certified dermatologist Dr Jeffrey Dover commented, “Topical therapies yield temporary results and oral medications present several challenges. AviClear offers patients a safe, well-tolerated, drug-free approach with durable results, which significantly shifts the treatment paradigm for acne.”

Dermalux Compact Lite by Aesthetic Technology Ltd

About This new LED device uses Tri-Wave MD technology to reduce redness and hyperpigmentation, as well as rejuvenate blemish-prone skin. The product has an adjustable LED panel design, which enables versatile positioning for use with a treatment couch or chair.

The science In a clinical study of the Tri-Wave MD device, 20 adult patients were treated for facial hypervascularisation separated into a LED-group and IPL-group. Results showed that treatment with combined red and near-infrared light-emitting diodes reduced the excess of facial vascularisation with moderate outcomes compared to IPL (70% of the results within four weeks compared to three months of IPL treatment).3

What practitioners say Dr Aneesha Ahmaed, director at Skyn Doctor, said, “We are seeing improvements in skin conditions after three treatments. I would recommend the Dermalux Tri-Wave MD device and look forward to the launch of the Compact Lite device.”

Dermatopoietin skincare by Evenswiss UK

About This is a new skincare range based on patented technology Dermatopoietin, which aims to mimic a natural signalling cytokine found in the skin and help regulate the tissue and regeneration. Every product contains Dermatopoietin, however, each is tailored to different skin concerns. The range includes cleansing products, skincare and haircare, from serums to shampoos.

The science In a clinical study of 22 female volunteers, all showed a significant increase of skin density accompanied by an average increase of skin elasticity by 15-21% after 28 and 56 days, respectively.4

What practitioners say Miss Rachna Murthy, consultant oculoplastic and aesthetic surgeon at Face Restoration, said, “We’re delighted to offer our patients Evenswiss products. The brand has developed a cult following among patients who have found a reduction in redness and puffiness of the under-eye area with the Rejuvenating Eye Complex and Rejuvenating Serum as early as two weeks after beginning use.”

Human Health by Dr Mayoni Gooneratne

About Founded by aesthetic practitioner Dr Mayoni Gooneratne, Human Health is the health and wellness arm of her aesthetic clinic. The focus is on the importance of implementing mental health support in aesthetic clinics, while introducing more wellness-focused services such as weight management and health supplements.

The science More than 97% of 68 people have seen a significant change in their health outcomes, and a further 98% of people would recommend the service to family and friends.6

What practitioners say Dr Gooneratne said, “Without wellness, we are nothing. What we see and hear in aesthetic clinics is patients unhappy with their skin, but that’s only because they can see something’s not right with it. It’s so important to address wellness first, and I hope to see this developing over the coming years.”

HArmonyCa by Allergan Aesthetics

About HArmonyCa is a hybrid injectable treatment combining hyaluronic acid (HA) and calcium hydroxyapatite (CaHA). The product offers a dual effect, with the HA causing immediate lifting and the CaHA stimulating new collagen production. According to the company, the product is intended for facial soft tissue augmentation via injection into deep dermal and sub-dermal layers.

The science In a study conducted by Allergan Aesthetics, more than 90% of 162 patients reported an improvement in the general appearance of facial areas following treatment.5

What practitioners say Aesthetic practitioner at PHI Clinic Dr Tapan Patel said, “I always felt there was a missing piece from the treatments we had to offer our patients. We had great innovations for building volume, treating pigmentation and improving skin texture, but there were a lot of patients who we couldn’t help. That’s why we have a place for the new hybrid HArmonyCa collagen-stimulating injectable, which combines CaHA and HA in a single syringe for both an immediate and sustained lifting effect.”

HIT methodology by Galderma

About Taking a new holistic approach towards aesthetics, Galderma teaches the use of AART – Assessment, Anatomy, Range and Treatment in order to deliver its new concept ‘Holistic Individualised Treatments’ (HITs). The aim is to provide a simplified approach to facial aesthetic needs based on cross-usage of products for different areas of concern.

The science Using the Restylane Eyelight products, 88.6% of 3,265 people reported looking less tired and 91.4% of people still felt attractive due to the improvement in their dark circles after six and a half months after the first treatment.7

What practitioners say Aesthetic trainer at Acquisition Aesthetics Miss Priya Chadha said, “Galderma is launching HITs to the aesthetics world – a holistic approach towards treatment for patients, following a methodology that helps patients discover how treatments can work in conjunction to achieve natural and beautiful results.”

TIME+ by Nuchido

About A new oral supplement which aims to restore cellular nicotinamide adenine dinucleotide (NAD+) levels, slowing ageing and transforming skin from the inside. According to the company, the supplement increases the body’s NAD+ levels to support cellular function and maintain health and performance.

The science NAD+ levels were measured in the blood cells of two human volunteers before, during and after taking Nuchido TIME+ for 16 days. During the 16-day supplement period, NAD+ levels increased by an average of 242% above baseline levels.8

What practitioners say Dr Steven Land, aesthetic practitioner at Novellus Aesthetics, commented, “The insights I’ve gained from Nuchido have really educated me on the emerging field of cellular ageing and the latest best practice in addressing it. This has helped me not only diversify my current services, but also consider how my business needs to develop in the future to stay current and capture this new market coming to the UK.”

SUPERB technology by Sofwave

About Receiving clearance from the US FDA, the SUPERB technology by Sofwave aims to lift the eyebrow, lax submental and neck tissue while improving facial lines and wrinkles. The technology generates heat at the appropriate depth to trigger neocollagenesis, which increases and regenerates collagen in the skin for a rejuvenated effect.

The science A clinical study evaluating SUPERB technology in treating facial lines and wrinkles took place by the company. 60 patients were enrolled, with 58 completing the study across two sites. Results demonstrated that the blinded reviewers correctly identified the pre- and post-treatment photographs for 78% of treated subjects, and assessed a reduction of a least one unit using the Fitzpatrick Wrinkle and Elastosis Scale in 78%.10

What practitioners say Dr Munir Somji, founder and director of Dr MediSpa clinics, explained, “I have always been an advocate of ultrasound technology to help improve the skin for some of the most common concerns – laxity, fine lines and wrinkles and overall tone and texture. Not all ultrasound is created equal, and Sofwave has managed to achieve exactly what is needed to get optimal results with just the right amount of energy and depth.”

Topilase by Prollenium

About Topilase is a topical hyaluronidase enzymatically complexed with botanical polysaccharides that can dissolve HA filler. The product, created by Canadian-based filler manufacturer Prollenium, is a skin serum which aims to allow minor filler complications to be corrected without risk or trauma.

The science In a clinical study, 17 females aged 23-54 with chronic post-filler contour irregularities received one to three topical treatments with Topilase. Two to four weeks after final treatment, physician-assessed contour improvement was 8-10/10 for seven patients, 5-7/10 for six, 1-4/10 for three and 0/10 for one patient. 15 patients evaluated their skin as more uniform. Satisfaction scores were 7-10/10 for 13 patients, 6/10 for two and 0-1/10 for two.9

What practitioners say Dr Emily Mehta, medical director of Harley Academy and STORY clinics, said, “Topilase is particularly useful in the under-eye and lip areas, which is where I see more than 90% of filler problems. Both areas are easily over-treated by less experienced practitioners and can also occasionally cause product migration. The process is completely painless – it is simply a serum that is rubbed into the area where filler needs to be reduced or removed.”

VIEW THE REFERENCES ONLINE! AESTHETICSJOURNAL.COM

To find out more about the innovations, as well as the trends over the past year, scan the QR code to read the full Trends Report released at CCR.

go go go go go go

new ways new ways

Letybo® brings practitioners a new option to the current aesthetic market brings practitioners a new option to the current aesthetic market and provides aesthetic professionals and their patients with a notable and provides aesthetic professionals and their patients with a notable effi cacy and confi rmed tolerability.1,2,*effi cacy and confi rmed tolerability.

94% response rate 4 weeks post injection 1,** 1,** Proven consistent effi cacy and tolerability with Proven consistent effi cacy and tolerability with repeated injections for up to 12 months 1,2 Demonstrated high patient satisfaction2

*Letybo® is indicated for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows in adults <75 years old seen at maximum frown (glabellar lines), when the severity of the facial lines has an important psychological impact. **Response rate was defi ned as a ≥ 1-point reduction in FWS at maximum Scan for Reconstitution frown based on the investigators assessment. References: 1. Mueller DS, Prinz V, Adelglass J, Cox SE, Gold M, Kaufman-Janette J et al. Effi cacy and Safety of Letibotulinum Toxin A in the Treatment of Glabellar Lines: A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study. Aesthet Surg J. 2022; 42(6): 677- 88. ; 2. Letybo® smPC, https://www.medicines.org.uk/emc/product/13707 2022 Instructions Letybo 50 units powder for solution for injection; Abbreviated Prescribing Information: Please refer to the Summary of Product Characteristics (SmPC) before prescribing. Presentation: One vial contains 50 units botulinum toxin type A produced by Clostridium botulinum. After reconstitution each 0.1 mL of the solution contains 4 units. Indication: For the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows in adults <75 years old seen at maximum frown (glabellar lines), when the severity of the facial lines has an important psychological impact. Dosage and administration: Should only be administered by physicians with expertise in this treatment. Posology: The recommended dose is a total of 20 units divided into fi ve injections of 4 units (0.1 mL) each: 2 injections in each corrugator supercilii muscle and 1 injection in the procerus muscle. Botulinum toxin units are not interchangeable from one product to another. Doses recommended are different from other botulinum toxin preparations. Treatment interval should not be more frequent than every three months. In the absence of any undesirable effects secondary to the previous treatment session, a further treatment session with at least a three-month interval between the treatment sessions is possible. The effi cacy and safety of repeat injections beyond 12 months has not been evaluated. Special populations: No specifi c dose adjustment is required for use in the elderly older than 65 years of age. Letybo is contraindicated in patients 75 years or older. There is no relevant use in the paediatric population. Method of administration: Intramuscular use. Care should be taken to ensure that Letybo is not injected into a blood vessel. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Generalised disorders of muscle activity (e.g. myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis). Presence of acute infection or infl ammation at the proposed injection sites. Patients with bleeding disorders. Warnings and Precautions: Injection into vulnerable anatomic structures must be avoided. Avoid use when the muscle shows excessive weakness or atrophy. Risk of eyelid ptosis following treatment. Procedurerelated events: Needle-related pain and/or anxiety have resulted in vasovagal responses, including transient symptomatic hypotension and syncope after treatment with other botulinum toxins. Pre-existing neuromuscular disorders: Patients with unrecognised neuromuscular disorders may be at increased risk of clinically signifi cant systemic effects including severe dysphagia and respiratory compromise from typical doses of botulinum toxin type A. Hypersensitivity reactions: An anaphylactic reaction may occur after injection of botulinum toxin. Epinephrine (adrenaline) or any other anti-anaphylactic measures should therefore be available. Local or distant spread of toxin effects: Adverse reactions possibly related to the spread of toxin distant from the site of administration have been reported. Patients may experience exaggerated muscle weakness. Swallowing and breathing diffi culties are serious and can result in death. Use not recommended in patients with a history of dysphagia and aspiration. Patients should be advised to seek immediate medical care if swallowing, speech or respiratory disorders arise. Pregnancy & Lactation: Not recommended during pregnancy or lactation and in women of childbearing potential not using contraception. Undesirable effects: Most common effects are headache and injection site reaction. Very rarely aspirational pneumonia. For full list of side effects, consult SmPC. Legal Category: POM; Pack size: Packs containing 1 5ml vial. Multipack containing 2 (2 packs of 1) vials; Price list: UK - 1x5ml: 65GBP, 2x5ml: 120GBP; MA Number: PL 29863/0002; PA Number: PA0846/001/001; MA Holder: Croma-Pharma GmbH, Industriezeile 6, 2100 Leobendorf, Austria; Date of preparation: 11/04/2022; Unique ID no CRP001/001;

Adverse events should be reported. Reporting forms and information can be found at: UK - http://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.

IE - HPRA Pharmacovigilance Website: www.hpra.ie. Adverse events should also be reported to Croma Pharma GmbH on 0118 206 6513

® is indicated for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows in adults <75 years old seen at maximum Response rate was defi ned as a ≥ 1-point reduction in FWS at maximum Reconstitution Toxin A in the Treatment of Glabellar Lines: A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study. Aesthet Surg J. 2022; 42(6): 677- 88. ; 2. Letybo® One vial contains 50 units botulinum toxin type A produced by Clostridium botulinum. After reconstitution each 0.1 mL of the solution contains For the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows in adults <75 years old seen at maximum Should only be administered by physicians with expertise in this treatment. recommended dose is a total of 20 units divided into fi ve injections of 4 units (0.1 mL) each: 2 injections in each muscle and 1 injection in the muscle. Botulinum toxin units are not interchangeable secondary to the previous treatment session, a further treatment session with at least a three-month interval between the treatment sessions is possible. The effi cacy and safety of repeat injections beyond 12 months has Intramuscular use. Care should be taken to ensure that Letybo is not injected into a blood vessel. excipients. Generalised disorders of muscle activity (e.g. myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis). Presence of acute infection or infl ammation at the proposed injection sites. Patients with bleeding disorders. Injection into vulnerable anatomic structures must be avoided. Avoid use when the muscle shows excessive weakness or atrophy. Risk of eyelid ptosis following treatment. Needle-related pain and/or anxiety have resulted in vasovagal responses, including transient symptomatic hypotension and syncope after treatment with other botulinum toxins. Pre-existing neuromuscular Patients with unrecognised neuromuscular disorders may be at increased risk of clinically signifi cant systemic effects including severe dysphagia and respiratory compromise from typical doses of botulinum toxin An anaphylactic reaction may occur after injection of botulinum toxin. Epinephrine (adrenaline) or any other anti-anaphylactic measures should therefore be available. Adverse reactions possibly related to the spread of toxin distant from the site of administration have been reported. Patients may experience exaggerated muscle weakness. Swallowing and breathing diffi culties are serious and can result in death. Use not recommended in patients with a history of dysphagia and aspiration. Patients should be advised to seek immediate medical care if swallowing, speech or respiratory disorders Most common effects are headache and injection site

Adverse events should be reported. Reporting forms and information can be found at: UK - http://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.

IE - HPRA Pharmacovigilance Website: www.hpra.ie. Adverse events should also be reported to Croma Pharma GmbH on 0118 206 6513